Becton Dickinson and Company (BDX)

240.08
-3.53(-1.45%)
  • Volume:
    1,473,712
  • Bid/Ask:
    240.00/240.16
  • Day's Range:
    239.44 - 244.38

BDX Overview

Prev. Close
243.61
Day's Range
239.44-244.38
Revenue
20.25B
Open
242.75
52 wk Range
234.61-267.37
EPS
6.85
Volume
1,473,712
Market Cap
68.09B
Dividend (Yield)
3.48
(1.42%)
Average Vol. (3m)
1,343,414
P/E Ratio
35.58
Beta
0.71
1-Year Change
6.4%
Shares Outstanding
284,023,582
Next Earnings Date
Feb 03, 2022
What is your sentiment on Becton Dickinson and Company?
or
Vote to see community's results!

Becton Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company’s BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company’s BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is based in Franklin Lakes, New Jersey.

Read More

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellStrong SellStrong SellStrong SellSell
Technical IndicatorsStrong BuyStrong SellStrong SellStrong SellSell
SummaryStrong SellStrong SellStrong SellStrong SellSell
  • Can someone tell me the difference between this stock and AMBU(danish company). Becides the fact that AMBU is valued 1/5 of BDX…
    0
    • anyone an idea for a target?
      0
      • $240
        0
    • https://www.fool.com/investing/2021/02/27/these-3-stocks-big-winners-from-president-biden/?source=eptyholnk0000202&utm_source=yahoo-host&utm_medium=feed&utm_campaign=article
      0
      • Last chance to get in , DPA will give a big boost in a few weeks.
        1
        • Rajeesh Raju good luck
          0
        • Lode Schepershttps://www.nasdaq.com/articles/becton-dickinson-gets-eua-for-new-diagnostic-test-2021-02-14
          0
        • Rajeesh Raju Thank you very much. Succes!
          0
      • bye bye b d x you stepped on Elon Musk toes
        2
        • what happened ?
          0
      • https://www.biospace.com/article/releases/cardiff-oncology-prices-public-offering-sep-30-2020/
        0
        • 300$ by end of 2020
          1
          • We need to see at least 230 before its worth getting into.
            2
            • insane earnings, insane share price, insane P/E ratio
              0
              • P/E isn't insane, 91 is without NRI, forward P/E is 20. At 15 it would be a good entry point but the price would have to be $180.
                0
            • . I want to know if this asset comes in at 192 this week? What do you guys think?
              0
              • I would pull the trigger at $180 with a forward P/E of 15.
                0
            Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
            Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.